Blockchain Registration Transaction Record

VolitionRx Partners with Werfen to Advance APS Diagnostic Testing

VolitionRx partners with Werfen to develop advanced diagnostic testing for antiphospholipid syndrome using innovative Nu.Q NETs assay technology for improved patient care.

This collaboration represents a significant advancement in autoimmune disease diagnostics that could transform how antiphospholipid syndrome is detected and managed. For the approximately 4 million people affected by APS worldwide, this partnership could lead to earlier and more accurate diagnosis, better thrombosis risk assessment, and improved treatment monitoring. Current APS diagnosis requires two positive antibody tests weeks apart, creating diagnostic delays that this new biomarker approach could eliminate. The potential for improved patient outcomes through earlier intervention and better disease management makes this development crucial for both patients and healthcare providers in the autoimmune disease space.